Hologic will approach the US FDA next week for the emergency use authorisation of Aptima SARS-CoV-2 assay. Credit: CDC / Unsplash.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hologic is set to launch a new Aptima molecular assay that will run on the Panther system for the detection of SARS-CoV-2 virus, which causes Covid-19.

The Panther system is a fully automated, high-throughput molecular diagnostic platform installed in 60 countries and 50 states in the US.

It can deliver initial results in three hours and can process over 1,000 coronavirus tests a day.

Hologic aims to scale up the testing capabilities in the US by combining its manufacturing capacity for the new test with its existing high-throughput molecular instruments across the country.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will begin distributing a research use only (RUO) version of the test to the hospitals next week. The test will also be available to reference laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity tests.

Hologic chairman, president and CEO Steve MacMillan said: “Our second Covid-19 test leverages the same proprietary Aptima chemistry and Panther instrumentation that have made Hologic a leader in molecular diagnostics for other infectious diseases.”

The company said that it will approach the US Food and Drug Administration (FDA) next week for the emergency use authorisation (EUA) of Aptima SARS-CoV-2 assay.

Hologic also plans to register a CE Mark for diagnostic use in Europe next month.

Initially, Hologic will provide three million RUO Covid-19 detection tests to its laboratory customers in the US. The company aims to manufacture an average of at least one million Aptima SARS-CoV-2 assays a week from next month. It plans to scale up the production further in the coming months.

In March, Hologic received EUA for its first Covid-19 test, the Panther Fusion SARS-CoV-2 assay.